Brokerages Expect TherapeuticsMD Inc (NASDAQ:TXMD) to Announce ($0.11) EPS
TherapeuticsMD Inc (NASDAQ:TXMD) has been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $15.63 for the company and are forecasting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given TherapeuticsMD an industry rank of 97 out of 265 based on the ratings given to its competitors.
A number of research firms have weighed in on TXMD. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, September 3rd. Jefferies Group reissued a “buy” rating on shares of TherapeuticsMD in a report on Wednesday, June 8th. Finally, Noble Financial reissued a “buy” rating and issued a $17.50 target price on shares of TherapeuticsMD in a report on Monday, July 11th.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 6.26 on Tuesday. TherapeuticsMD has a 12 month low of $5.18 and a 12 month high of $11.26. The company’s market cap is $1.23 billion. The stock’s 50 day moving average price is $6.97 and its 200-day moving average price is $7.64.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The firm earned $4.40 million during the quarter, compared to analysts’ expectations of $5.63 million. TherapeuticsMD’s quarterly revenue was down 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. Equities research analysts expect that TherapeuticsMD will post ($0.43) earnings per share for the current year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.